Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Program Overview

This activity begins by providing guidance on identifying EGFR exon 20 insertion mutations in advanced non-small cell lung cancer (NSCLC) and information on their therapeutic relevance. New and emerging therapeutic options are discussed, with an emphasis on the most recently presented and/or published clinical data. Learners will also receive privileged insights into the optimal management of potential adverse effects.

Credit Expired

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze the predictive/prognostic significance of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
  • Apply optimal diagnostic strategies for identifying NSCLC with EGFR exon 20 insertions
  • Assess clinical trial data regarding new and emerging treatment options for advanced NSCLC with EGFR exon 20 insertions
  • Employ appropriate techniques to manage adverse events associated with EGFR inhibition

Activity Faculty


Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO

Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China


Shirish M. Gadgeel, MD

Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI


Antonio Passaro, MD, PhD

Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources